{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:54:53Z","timestamp":1794621293372,"version":"4.9.1"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.eclinm.2026.103921","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:52:52Z","timestamp":1777020772000},"page":"103921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Prediction of trajectories and outcomes in early-stage metabolic dysfunction-associated steatotic liver disease: a narrative review"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7808-2093","authenticated-orcid":false,"given":"Brittany","family":"Bromfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Chimene-Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Gheewalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie K.","family":"Mitten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-1471","authenticated-orcid":false,"given":"Piero","family":"Portincasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8334-0400","authenticated-orcid":false,"given":"Gyorgy","family":"Baffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.103921_bib1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103921_bib3","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.eclinm.2026.103921_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.eclinm.2026.103921_bib5","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.14309\/ajg.0000000000003274","article-title":"Cardiovascular risk from metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factor count, and their longitudinal changes: a nationwide cohort study","volume":"120","author":"Lee","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.eclinm.2026.103921_bib6","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.eclinm.2026.103921_bib7","article-title":"Prognostic utility of Fibrosis-4 index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study","volume":"36","author":"Anstee","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.eclinm.2026.103921_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","article-title":"AASLD practice guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.eclinm.2026.103921_bib9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American diabetes association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eclinm.2026.103921_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba4448","article-title":"Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis","volume":"12","author":"Govaere","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eclinm.2026.103921_bib11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/joim.12719","article-title":"Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver","volume":"283","author":"Dongiovanni","year":"2018","journal-title":"J Intern Med"},{"key":"10.1016\/j.eclinm.2026.103921_bib13","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib15","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.29546","article-title":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study","volume":"67","author":"Allen","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.eclinm.2026.103921_bib16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib17","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.eclinm.2026.103921_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14276","article-title":"Association of MASLD with the risk of extrahepatic cancers: a systematic review and meta-analysis of 18 cohort studies","volume":"54","author":"Zhou","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.eclinm.2026.103921_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/science.adp7977","article-title":"Medical forecasting","volume":"384","author":"Topol","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.eclinm.2026.103921_bib20","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1038\/s41598-025-89293-6","article-title":"Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults","volume":"15","author":"Chung","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2026.103921_bib21","article-title":"All-cause and disease-specific mortality in young adults with MASLD: a nationwide cohort study","volume":"7","author":"Park","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.eclinm.2026.103921_bib22","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S2468-1253(22)00020-6","article-title":"Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review","volume":"7","author":"Abeysekera","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jhep.2025.10.015","article-title":"Closing the gap: why liver health must be central to the United Nations political declaration on non-communicable diseases","volume":"84","author":"Krag","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib24","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1038\/ncomms5022","article-title":"Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients","volume":"5","author":"Jensen","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2026.103921_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fbinf.2023.1112113","article-title":"Visualising disease trajectories from population-wide data","volume":"3","author":"Hjaltelin","year":"2023","journal-title":"Front Bioinform"},{"key":"10.1016\/j.eclinm.2026.103921_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jclinepi.2021.01.009","article-title":"Clinical prediction models: diagnosis versus prognosis","volume":"132","author":"van Smeden","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2026.103921_bib27","doi-asserted-by":"crossref","first-page":"710","DOI":"10.14309\/ajg.0000000000003595","article-title":"Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease","volume":"121","author":"Barritt","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.eclinm.2026.103921_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eclinm.2026.103921_bib29","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/s41598-022-06205-8","article-title":"Relationship between the dynamics of non-alcoholic fatty liver disease and incident diabetes mellitus","volume":"12","author":"Han","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2026.103921_bib30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1210\/jc.2015-3111","article-title":"Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD","volume":"101","author":"Bril","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eclinm.2026.103921_bib31","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American heart association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.eclinm.2026.103921_bib32","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","article-title":"Multiomics study of nonalcoholic fatty liver disease","volume":"54","author":"Sveinbjornsson","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.eclinm.2026.103921_bib33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jhep.2024.06.030","article-title":"Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer","volume":"81","author":"Ahmed","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2023.04.035","article-title":"A global research priority agenda to advance public health responses to fatty liver disease","volume":"79","author":"Lazarus","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib35","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cgh.2025.09.002","article-title":"Projected global clinical, humanistic, and economic impact of metabolic dysfunction-associated steatohepatitis (MASH): the cost of inaction based on data from nine countries","volume":"24","author":"Younossi","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib36","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.cgh.2024.05.052","article-title":"Genetics of metabolic dysfunction-associated steatotic liver disease: the state of the art update","volume":"22","author":"Sookoian","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib37","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s42255-025-01394-8","article-title":"Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism","volume":"7","author":"Mancina","year":"2025","journal-title":"Nat Metab"},{"key":"10.1016\/j.eclinm.2026.103921_bib38","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41588-022-01078-z","article-title":"A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation","volume":"54","author":"Vujkovic","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.eclinm.2026.103921_bib40","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","article-title":"Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Jamialahmadi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2026.103921_bib41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.cgh.2021.05.056","article-title":"A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores","volume":"20","author":"De Vincentis","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib42","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2020.01.053","article-title":"Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA3 and beyond","volume":"158","author":"Krawczyk","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2026.103921_bib43","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstrom","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib44","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative metabolism in MASLD and MASH: pathophysiology and emerging mechanisms","volume":"83","author":"Steinberg","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib45","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/hep.27376","article-title":"Liver sinusoidal endothelial cells in hepatic fibrosis","volume":"61","author":"DeLeve","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.eclinm.2026.103921_bib46","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2026.103921_bib47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jhepr.2019.02.004","article-title":"Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism","volume":"1","author":"Lefere","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.eclinm.2026.103921_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032785","article-title":"Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD","volume":"7","author":"Pasarin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2026.103921_bib49","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/labinvest.2015.95","article-title":"Pivotal role of liver sinusoidal endothelial cells in NAFLD\/NASH progression","volume":"95","author":"Miyao","year":"2015","journal-title":"Lab Invest"},{"key":"10.1016\/j.eclinm.2026.103921_bib50","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2026.103921_bib51","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10620-017-4903-5","article-title":"Origins of portal hypertension in nonalcoholic fatty liver disease","volume":"63","author":"Baffy","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.eclinm.2026.103921_bib52","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jhep.2019.02.012","article-title":"Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease","volume":"70","author":"Hammoutene","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib53","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.jhep.2022.08.028","article-title":"Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease","volume":"77","author":"Mitten","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib54","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12072-017-9798-x","article-title":"Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg","volume":"12","author":"Arab","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.eclinm.2026.103921_bib55","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/metabo14060324","article-title":"Gut microbiota and sinusoidal vasoregulation in MASLD: a portal perspective","volume":"14","author":"Baffy","year":"2024","journal-title":"Metabolites"},{"key":"10.1016\/j.eclinm.2026.103921_bib56","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.3390\/ijms26168081","article-title":"Metabolic dysfunction-associated steatotic liver disease: a silent driver of cardiovascular risk and a new target for intervention","volume":"26","author":"Gallo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eclinm.2026.103921_bib57","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jhep.2024.11.034","article-title":"New evidence of cross-disease communication between heart and liver","volume":"82","author":"Marjot","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib58","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2026.103921_bib59","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrgastro.2013.182","article-title":"The genetics of NAFLD","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s42255-022-00731-5","article-title":"A phenome-wide comparative analysis of genetic discordance between obesity and type 2 diabetes","volume":"5","author":"Coral","year":"2023","journal-title":"Nat Metab"},{"key":"10.1016\/j.eclinm.2026.103921_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156306","article-title":"Impact of metabolic dysfunction severity in steatotic liver disease and its interaction with liver fibrosis on all-cause mortality and multiple hepatic and extra-hepatic outcomes","volume":"170","author":"Cuthbertson","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.eclinm.2026.103921_bib62","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome\u2014a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.103921_bib63","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/apt.18205","article-title":"Cardiometabolic criteria as predictors and treatment targets of liver-related events and cardiovascular events in metabolic dysfunction-associated steatotic liver disease","volume":"60","author":"Tamaki","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2026.103921_bib64","article-title":"Differential effects of cardiometabolic risk factors on all-cause mortality in United States adults with metabolic dysfunction-associated steatotic liver disease (MASLD)","author":"Dukewich","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1244405","article-title":"Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease","volume":"14","author":"Semmler","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eclinm.2026.103921_bib66","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00125-019-05024-3","article-title":"Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality","volume":"63","author":"Brouwers","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.eclinm.2026.103921_bib67","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/ng.3977","article-title":"Exome-wide association study of plasma lipids in >300,000 individuals","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.eclinm.2026.103921_bib68","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/jgh.16326","article-title":"Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning","volume":"38","author":"Ito","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib69","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41588-023-01497-6","article-title":"Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease","volume":"55","author":"Chen","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.eclinm.2026.103921_bib70","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/jgh.16552","article-title":"Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis","volume":"39","author":"Mori","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib71","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000016","article-title":"Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease","volume":"7","author":"Yi","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.eclinm.2026.103921_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155294","article-title":"Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: a data-driven cluster analysis with international validation","volume":"136","author":"Ye","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.eclinm.2026.103921_bib73","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2026.103921_bib74","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2026.103921_bib75","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","article-title":"Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study","volume":"7","author":"Zaharia","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2026.103921_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.713592","article-title":"Machine learning to identify metabolic subtypes of obesity: a multi-center study","volume":"12","author":"Lin","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eclinm.2026.103921_bib77","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41591-020-1116-9","article-title":"Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes","volume":"27","author":"Wagner","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2026.103921_bib78","article-title":"Novel subgroups and chronic complications of diabetes in middle-aged and elderly Chinese: a prospective cohort study","volume":"12","author":"Wang","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eclinm.2026.103921_bib79","article-title":"Identification of the non-alcoholic fatty liver disease molecular subtypes associated with clinical and immunological features via bioinformatics methods","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2026.103921_bib80","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067203","article-title":"Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality: unsupervised machine learning analysis of NHANES III","volume":"12","author":"Carrillo-Larco","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.eclinm.2026.103921_bib81","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/17474124.2023.2191190","article-title":"Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making","volume":"17","author":"Pirola","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib82","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s12020-025-04200-3","article-title":"Cluster analysis of diet and lifestyle factors associated with metabolic dysfunction-associated steatotic liver disease: findings from Korean Genome and Epidemiology Study","volume":"88","author":"Lee","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.eclinm.2026.103921_bib83","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1111\/dom.70095","article-title":"Investigating multimorbidity trajectories in people living with MASLD diagnosis: a trajectory analysis using the UK Biobank","volume":"27","author":"Lu","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eclinm.2026.103921_bib84","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70305","article-title":"Metabolic divergence between MASLD and metabolic syndrome: distinct clinical phenotypes and risk stratification implications","volume":"45","author":"Ramirez-Mejia","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.eclinm.2026.103921_bib85","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib86","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","article-title":"Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD","volume":"80","author":"Ratziu","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib87","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"Marti-Aguado","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib88","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.cgh.2025.02.007","article-title":"Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments","volume":"23","author":"Israelsen","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib89","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000112","article-title":"Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories","volume":"7","author":"Kantartzis","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.eclinm.2026.103921_bib90","first-page":"226","article-title":"Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine","volume":"22","author":"Stefan","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib91","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2147\/CLEP.S265287","article-title":"Trajectory modelling techniques useful to epidemiological research: a comparative narrative review of approaches","volume":"12","author":"Nguena Nguefack","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2026.103921_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2022.103986","article-title":"Stratifying individuals into non-alcoholic fatty liver disease risk levels using time series machine learning models","volume":"126","author":"Ben-Assuli","year":"2022","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.eclinm.2026.103921_bib93","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1038\/s41467-020-18682-4","article-title":"Disease trajectory browser for exploring temporal, population-wide disease progression patterns in 7.2 million Danish patients","volume":"11","author":"Siggaard","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2026.103921_bib94","article-title":"Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake","volume":"7","author":"Hansen","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.eclinm.2026.103921_bib95","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v32.i2.111737","article-title":"Artificial intelligence in metabolic dysfunction-associated steatotic liver disease: transforming diagnosis and therapeutic approaches","volume":"32","author":"Hernandez-Almonacid","year":"2026","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.eclinm.2026.103921_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106175","article-title":"The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease","volume":"98","author":"Hardy","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.eclinm.2026.103921_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299487","article-title":"Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information","volume":"19","author":"McTeer","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2026.103921_bib98","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.231092","article-title":"Repeatability of MRI biomarkers in nonalcoholic fatty liver disease: the NIMBLE consortium","volume":"309","author":"Fowler","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.eclinm.2026.103921_bib99","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/hep4.1689","article-title":"Patient determinants for histologic diagnosis of NAFLD in the real world: a TARGET-NASH study","volume":"5","author":"Barritt","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.eclinm.2026.103921_bib100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/omi.2010.0023","article-title":"Biomarkers in the age of omics: time for a systems biology approach","volume":"15","author":"Abu-Asab","year":"2011","journal-title":"OMICS"},{"key":"10.1016\/j.eclinm.2026.103921_bib101","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.cgh.2018.11.008","article-title":"Prevalence and severity of nonalcoholic fatty liver disease among caregivers of patients with nonalcoholic fatty liver disease cirrhosis","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib102","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.14309\/ajg.0000000000003421","article-title":"Social determinants of health associated with metabolic dysfunction-associated steatotic liver disease prevalence and severity: a systematic review and meta-analysis","volume":"120","author":"Abu-Rumaileh","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.eclinm.2026.103921_bib103","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3390\/ijms26041589","article-title":"Unraveling metabolic dysfunction-associated steatotic liver disease through the use of omics technologies","volume":"26","author":"Bourganou","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eclinm.2026.103921_bib104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003149","article-title":"Predicting and elucidating the etiology of fatty liver disease: a machine learning modeling and validation study in the IMI DIRECT cohorts","volume":"17","author":"Atabaki-Pasdar","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.eclinm.2026.103921_bib105","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jhep.2022.10.035","article-title":"Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease","volume":"78","author":"Cholankeril","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib106","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.eclinm.2026.103921_bib107","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib108","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2026.01.047","article-title":"Clinical care pathway for the risk stratification and management of patients with metabolic dysfunction-associated steatotic liver disease","author":"Kanwal","year":"2026","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2026.103921_bib109","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jhep.2025.01.014","article-title":"Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease","volume":"83","author":"Yip","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib110","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jhep.2019.08.019","article-title":"Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia","volume":"71","author":"Serra-Burriel","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib111","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.eclinm.2026.103921_bib112","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","article-title":"Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease","volume":"79","author":"Kjaergaard","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib113","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001400","article-title":"Detecting at-risk steatotic liver disease and liver fibrosis in the community","author":"Adams","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.eclinm.2026.103921_bib114","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2021.06.045","article-title":"Maternal obesity increases the risk and severity of NAFLD in offspring","volume":"75","author":"Hagstrom","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib115","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S2468-1253(17)30142-5","article-title":"Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease","volume":"3","author":"Rowe","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2026.103921_bib116","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000487","article-title":"Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction-associated steatotic liver disease","volume":"8","author":"Kaplan","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.eclinm.2026.103921_bib117","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/13543784.2025.2473062","article-title":"The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists","volume":"34","author":"Alkhouri","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.eclinm.2026.103921_bib118","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1038\/s41598-025-89408-z","article-title":"Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes","volume":"15","author":"Havranek","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.eclinm.2026.103921_bib119","series-title":"Clinical Relevance of Repeating FIB-4 in the Screening Strategy for Identifying MASLD-Related Advanced Fibrosis","author":"Chouik","year":"2026"},{"key":"10.1016\/j.eclinm.2026.103921_bib120","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2026.103921_bib121","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/apt.70020","article-title":"Addressing the high and rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): from the growing prevalence to payors\u2019 perspective","volume":"61","author":"Younossi","year":"2025","journal-title":"Aliment Pharmacol Ther"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026001690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026001690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:31:26Z","timestamp":1781670686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026001690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":121,"alternative-id":["S2589537026001690"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103921","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of trajectories and outcomes in early-stage metabolic dysfunction-associated steatotic liver disease: a narrative review","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103921"}}